López-Serrano Sergi, Cordoba Lorena, Pérez-Maillo Mónica, Pleguezuelos Patricia, Remarque Edmond J, Ebensen Thomas, Guzmán Carlos A, Christensen Dennis, Segalés Joaquim, Darji Ayub
IRTA, Centre de Recerca en Sanitat Animal (CReSA), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain.
Biomedical Primate Research Center, Department of Immunobiology, P.O. Box 3306, 2280 GH Rijswijk, The Netherlands.
Vaccines (Basel). 2021 Jul 6;9(7):751. doi: 10.3390/vaccines9070751.
This study aimed to evaluate the immune response and protection correlates against influenza virus (IV) infection in pigs vaccinated with the novel NG34 HA1 vaccine candidate adjuvanted with either CAF01 or CDA/αGalCerMPEG (αGCM). Two groups of six pigs each were vaccinated intramuscularly twice with either NG34 + CAF01 or NG34 + CDA/αGCM. As controls, groups of animals ( = 6 or 4) either non-vaccinated or vaccinated with human seasonal trivalent influenza vaccine or NG34 + Freund's adjuvant were included in the study. All animal groups were challenged with the 2009 pandemic (pdm09) strain of H1N1 (total amount of 7 × 10 TCID/mL) via intranasal and endotracheal routes 21 days after second vaccination. Reduced consolidated lung lesions were observed both on days three and seven post-challenge in the animals vaccinated with NG34 + CAF01, whereas higher variability with relatively more severe lesions in pigs of the NG34 + CDA/αGCM group on day three post-infection. Among groups, animals vaccinated with NG34 + CDA/αGCM showed higher viral loads in the lung at seven days post infection whereas animals from NG34 + CAF01 completely abolished virus from the lower respiratory tract. Similarly, higher IFNγ secretion and stronger IgG responses against the NG34 peptide in sera was observed in animals from the NG34 + CAF01 group as compared to the NG34 + CDA/αGCM. NG34-vaccinated pigs with adjuvanted CAF01 or CDA/αGCM combinations resulted in different immune responses as well as outcomes in pathology and viral shedding.
本研究旨在评估用新型NG34 HA1候选疫苗与CAF01或CDA/αGalCerMPEG（αGCM）佐剂联合接种的猪对流感病毒（IV）感染的免疫反应和保护相关性。两组猪，每组6头，分别肌肉注射两次NG34 + CAF01或NG34 + CDA/αGCM。作为对照，研究纳入了未接种疫苗、接种人季节性三价流感疫苗或NG34 +弗氏佐剂的动物组（每组6头或4头）。所有动物组在第二次接种后21天通过鼻内和气管内途径用2009年大流行（pdm09）H1N1毒株（总量为7×10 TCID/mL）进行攻毒。在攻毒后第3天和第7天，接种NG34 + CAF01的动物肺部实变损伤减轻，而在感染后第3天，NG34 + CDA/αGCM组猪的病变变异性更高且相对更严重。在各实验组中，接种NG34 + CDA/αGCM的动物在感染后7天肺部病毒载量更高，而NG34 + CAF01组的动物在下呼吸道完全清除了病毒。同样，与NG34 + CDA/αGCM组相比，NG34 + CAF01组动物血清中针对NG34肽的IFNγ分泌更高，IgG反应更强。接种NG34并佐以CAF01或CDA/αGCM组合的猪产生了不同的免疫反应以及病理和病毒排泄结果。
